Clinical trials and reports from individuals suggest AOD 9604 therapy has minimal to no significant side effects for most
Mwape, R
Some of these medications can also make the pre-existing symptoms even worse
Lastly, the limited evidence on the effects of GLP-1 RAs on key pathognomonic proteins, A and -synuclein, weakens the scientific basis for considering GLP-1 RAs as major game-changers for neurodegenerative diseases
Per the brand's Terms: "After reviewing your information, the Provider in their independent professional judgment, will determine whether to prescribe medication, other treatments, or, alternatively, recommend that you consult with alternative clinical resources." Prescription is not guaranteed
doi:10.5603/FHC.a2019.0002